Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

24.2%

8 terminated/withdrawn out of 33 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

21%

7 trials in Phase 3/4

Results Transparency

70%

14 of 20 completed trials have results

Key Signals

2 recruiting14 with results

Enrollment Performance

Analytics

Phase 2

14(50.0%)

N/A

5(17.9%)

Phase 4

4(14.3%)

Phase 3

3(10.7%)

Phase 1

2(7.1%)

28Total

Phase 2(14)

N/A(5)

Phase 4(4)

Phase 3(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT06052176Phase 2Recruiting

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

Role: collaborator

NCT05382650Terminated

Survey of Human Rabies Immune Globulin Safety in Children

Role: collaborator

NCT05152238Recruiting

ITP Registry and Accompanying Biospecimen Collection

Role: collaborator

NCT00323856Phase 4Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Role: lead

NCT05357339Not ApplicableCompleted

Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock

Role: collaborator

NCT03919773Phase 1Completed

IVIG (Gamunex-C) Treatment Study for POTS Subjects

Role: collaborator

NCT02915263Phase 2Terminated

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

Role: collaborator

NCT04621916Phase 4Unknown

Preventing Inhibitor Recurrence Indefinitely

Role: collaborator

NCT00555555Phase 4Active Not Recruiting

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Role: lead

NCT00319228Phase 2Active Not Recruiting

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

Role: lead

NCT03778840Completed

Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab

Role: collaborator

NCT04450654Phase 2Withdrawn

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Role: collaborator

NCT04899232Phase 2Terminated

Antithrombin III in Infectious Disease Caused by COVID-19

Role: collaborator

NCT03095287Phase 2Terminated

Alphanate in Immune Tolerance Induction Therapy

Role: collaborator

NCT04621123Phase 2Completed

Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients

Role: collaborator

NCT04213950Not ApplicableCompleted

Improving Adherence to Rabies PEP Guideline Recommendations

Role: collaborator

NCT01051076Not ApplicableCompleted

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

Role: collaborator

NCT02872142Phase 2Completed

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

Role: collaborator

NCT01051544Not ApplicableWithdrawn

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

Role: collaborator

NCT01731691Phase 2Terminated

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

Role: collaborator